VANCOUVER, BC – December 11, 2023 – ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased to announce that the Company’s common shares are now listed on the Frankfurt Stock Exchange (FSE) under the symbol Q9T.
“Listing on the Frankfurt Stock Exchange is an important step for the Company as it provides us with an opportunity to expand our investor base to Europe and provide greater liquidity while we continue to develop our novel myeloid cell focussed immuno-oncology drug candidates.” – Salim Dhanji, PhD, CEO
The Frankfurt Stock Exchange is one of the world’s largest trading centres for securities and is the largest exchange in Germany. The FSE facilitates advanced electronic trading, settlement and information systems and enables cross-border trading for international investors.
The Company would also like to announce that the redesign of its website is now complete and the site is now live. The new website provides a user- friendly place for investors to access information about the Company and its research programs.
ME Therapeutics Holdings Inc.
Myeloid Enhancement (ME) Therapeutics is an early stage Vancouver based biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. Our main focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells in order to enhance anti-cancer immunity. For more information, please visit www.metherapeutics.com and the Company’s profile on SEDAR+ at www.sedarplus.ca
ON BEHALF OF THE BOARD
“Salim Dhanji”
Dr. Salim Dhanji, PhD
Chief Executive Officer and Director
For further information, please contact:
Dr. Salim Dhanji
Telephone: (236) 516-7714
Forward Looking Statements
This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements in this news release include, but are not limited to, statements regarding the Company’s research plans, the timing for completion of studies and the receipt of results, the intended outcomes of the research, the intended benefits and applications of the Company’s technology, and the Company’s plans for development of its business. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including risks related to factors beyond the control of the Company, that the results of the testing are not favorable, that the research will not be completed within the expected timeline, G-CSF proves to be an unsuitable target to treat cancer, that the Company’s myeloid targeted prodrug candidates prove ineffective during testing, that the Company may require additional funding to advance its research and develop its business, and that the Company’s business may not develop as set out in this news release. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ from forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
